논문 목록
11건 · 최신순-
Repeat Administration and Dose Escalation of DaxibotulinumtoxinA in Adductor Type Laryngeal Dystonia.
[OBJECTIVES] During initial comparison of DaxibotulinumtoxinA-lanm (Daxi) to botulinum toxin A (BtxA) in adductor laryngeal dystonia (AdLD) (Phase 1), Daxi administration was found to be safe and efficacious. This study sought to determine …
-
Utility of Unified Spasmodic Dysphonia Rating Scale for Adductor Type Laryngeal Dystonia (AdLD).
[OBJECTIVE] The Unified Spasmodic Dysphonia Rating Scale (USDRS) was developed in 1997 to standardize evaluation of adductor-type laryngeal dystonia (AdLD) but has been sparsely utilized since then. The goal of this study was to explore the…
-
Comparing DaxibotulinumtoxinA to OnabotulinumtoxinA for Adductor Laryngeal Dystonia: A Pilot Study.
[OBJECTIVES] Botulinum toxin A (BtxA) injection for AdLD is typically performed approxiamately every 3 months. DaxibotulinumtoxinA-lanm (Daxi) is a peptide-formulated neuromodulator with reported longer therapeutic duration. This study comp…
-
DaxibotulinumtoxinA Treatment for Laryngeal Respiratory Dystonia.
[BACKGROUND] Laryngeal respiratory dystonia (LRD) is diagnosed based on clinical presentation, patient history, and physical examination. Key indicators include dyspnea, desynchronized breathing patterns, and laryngoscopic findings that rev…
-
Efficacy of Posterior Pharyngeal Wall Injection for Velopharyngeal Dysfunction in Adults.
[OBJECTIVE(S)] Posterior pharyngeal wall (PPW) injection is often employed to treat velopharyngeal deficiency (VPD). We sought to analyze the impact of PPW injection on severity of dysphagia and dysphonia. [METHODS] Retrospective chart rev…
-
Comparison of Outcome Measures (Subjective, Objective, and Patient-Based) in Laryngeal Dystonia Treatment With Botulinum Toxin A Injection.
[BACKGROUND] Outcome assessment in laryngeal dystonia is hindered by lack of consensus on a core set of outcome measures to quantify treatment effect and disease severity on quality of life. Potential outcome measure domains include objecti…
-
Exploring Patient's Preference of Patient-Reported Outcome Measures in Laryngeal Movement Disorders.
[BACKGROUND] Despite many available patient-reported outcome measures (PROMs) for laryngeal movement disorders, there is a lack of patient input regarding which PROM most accurately and conveniently captures aspects related to their vocal d…
-
Assessment of Patients Receiving Short-Interval Botulinum Toxin Chemodenervation Treatment for Laryngeal Dystonia and Essential Tremor of the Vocal Tract.
[IMPORTANCE] The gold-standard treatment for laryngeal dystonia (LD) and essential tremor of the vocal tract (ETVT) is botulinum toxin (BoNT) chemodenervation. Although safe and effective, it is not curative, and periodic injections are req…
-
Abnormal Laryngopharyngeal Sensation in Adductor Laryngeal Dystonia Compared to Healthy Controls.
[BACKGROUND/OBJECTIVES] Laryngeal sensory abnormality has been implicated as a component of adductor laryngeal dystonia (AdLD). The study objective was to assess laryngopharyngeal sensation in AdLD utilizing a calibrated, tactile aesthesiom…
-
Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
[BACKGROUND] Despite use of qualitative laryngeal electromyography (LEMG) guided botulinum toxin A (BoNT-A) injection for treatment of adductor spasmodic dysphonia (AdSD), unsatisfactory injections and complete "misses" remain problematic. …
-
Multidose Botulinum Toxin A for Intralaryngeal Injection: A Cost Analysis.
[OBJECTIVES] Botulinum toxin A (BtxA) injection is the mainstay treatment for laryngeal dystonias. BtxA product labeling states that reconstituted toxin should be used within 4 hours on a single patient despite several studies that have dem…